-
1
-
-
0035451307
-
Effect of rosuvastatin on low-density lipoprotein cholesterol in patients with hypercholesterolemia
-
Olsson A.G., Pears J., McKellar J., Mizan J., Raza A. Effect of rosuvastatin on low-density lipoprotein cholesterol in patients with hypercholesterolemia. Am J Cardiol. 88:2001;504-508.
-
(2001)
Am J Cardiol
, vol.88
, pp. 504-508
-
-
Olsson, A.G.1
Pears, J.2
Mckellar, J.3
Mizan, J.4
Raza, A.5
-
2
-
-
0028023417
-
The Eating Pattern Assessment Tool: A simple instrument for assessing dietary fat and cholesterol intake
-
Peters J.R., Quiter E.S., Brekke M.L., Admire J., Brekke M.J., Mullis R.M., Hunninghake D.B. The Eating Pattern Assessment Tool a simple instrument for assessing dietary fat and cholesterol intake . J Am Diet Assoc. 94:1994;1008-1013.
-
(1994)
J Am Diet Assoc
, vol.94
, pp. 1008-1013
-
-
Peters, J.R.1
Quiter, E.S.2
Brekke, M.L.3
Admire, J.4
Brekke, M.J.5
Mullis, R.M.6
Hunninghake, D.B.7
-
3
-
-
0015348189
-
Estimation of concentration of low-density lipoprotein cholesterol in plasma, without the use of the preparative ultracentrifuge
-
Friedewald W.T., Levy R.I., Frederickson D.S. Estimation of concentration of low-density lipoprotein cholesterol in plasma, without the use of the preparative ultracentrifuge. Clin Chem. 18:1972;499-502.
-
(1972)
Clin Chem
, vol.18
, pp. 499-502
-
-
Friedewald, W.T.1
Levy, R.I.2
Frederickson, D.S.3
-
5
-
-
0024549783
-
The Centers for Disease Control-National Heart, Lung, and Blood Institute Lipid Standardization Program: An approach to accurate and precise lipid measurements
-
Myers G.L., Cooper G.R., Winn C.L., Smith S.J. The Centers for Disease Control-National Heart, Lung, and Blood Institute Lipid Standardization Program an approach to accurate and precise lipid measurements . Clin Lab Med. 9:1989;105-135.
-
(1989)
Clin Lab Med
, vol.9
, pp. 105-135
-
-
Myers, G.L.1
Cooper, G.R.2
Winn, C.L.3
Smith, S.J.4
-
6
-
-
0001742423
-
Standardization of micromethods for plasma cholesterol, triglyceride and HDL-cholesterol with the clinics' methodology
-
(abstr)
-
Steiner P.M., Freidel J., Bremmer W., Stein E.A. Standardization of micromethods for plasma cholesterol, triglyceride and HDL-cholesterol with the clinics' methodology. (abstr) J Clin Chem Clin Biochem. 19:1981;850.
-
(1981)
J Clin Chem Clin Biochem
, vol.19
, pp. 850
-
-
Steiner, P.M.1
Freidel, J.2
Bremmer, W.3
Stein, E.A.4
-
7
-
-
0017811544
-
A comprehensive evaluation of the heparin manganese precipitation procedure for estimating high-density lipoprotein cholesterol
-
Warnick G., Albers J. A comprehensive evaluation of the heparin manganese precipitation procedure for estimating high-density lipoprotein cholesterol. J Lipid Res. 19:1978;65-76.
-
(1978)
J Lipid Res
, vol.19
, pp. 65-76
-
-
Warnick, G.1
Albers, J.2
-
8
-
-
0035897696
-
Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
-
Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA. 285:2001;2486-2497.
-
(2001)
JAMA
, vol.285
, pp. 2486-2497
-
-
-
10
-
-
0030972796
-
The rule of 5 and the rule of 7 in lipid lowering by statin drugs
-
Roberts W.C. The rule of 5 and the rule of 7 in lipid lowering by statin drugs. Am J Cardiol. 80:1997;106-107.
-
(1997)
Am J Cardiol
, vol.80
, pp. 106-107
-
-
Roberts, W.C.1
-
11
-
-
0038645309
-
Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial)
-
Jones P.H., Davidson M.H., Stein E.A., Bays H.E., McKenney J.M., Miller E., Cain V.A., Blasetto J.W. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial). Am J Cardiol. 92:2003;152-160.
-
(2003)
Am J Cardiol
, vol.92
, pp. 152-160
-
-
Jones, P.H.1
Davidson, M.H.2
Stein, E.A.3
Bays, H.E.4
Mckenney, J.M.5
Miller, E.6
Cain, V.A.7
Blasetto, J.W.8
-
12
-
-
0032032592
-
Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin and fluvastatin in patients with hypercholesterolemia (the CURVES Study)
-
Jones P., Kafonek S., Laurora I., Hunninghake D. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin and fluvastatin in patients with hypercholesterolemia (the CURVES Study). Am J Cardiol. 81:1998;582-587.
-
(1998)
Am J Cardiol
, vol.81
, pp. 582-587
-
-
Jones, P.1
Kafonek, S.2
Laurora, I.3
Hunninghake, D.4
-
13
-
-
0033562756
-
Effects of high doses of simvastatin and atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I
-
Crouse J.R., Frohlich J., Ose L., Mercuri M., Tobert J.A. Effects of high doses of simvastatin and atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I. Am J Cardiol. 83:1999;1476-1477.
-
(1999)
Am J Cardiol
, vol.83
, pp. 1476-1477
-
-
Crouse, J.R.1
Frohlich, J.2
Ose, L.3
Mercuri, M.4
Tobert, J.A.5
-
14
-
-
0035941786
-
Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): A prospective, randomised, double-blind trial
-
Smilde T.J., van Wissen S., Wollersheim H., Trip M.D., Kastelein J.J., Stalenhoef A.F. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP) a prospective, randomised, double-blind trial . Lancet. 357:2001;577-581.
-
(2001)
Lancet
, vol.357
, pp. 577-581
-
-
Smilde, T.J.1
Van Wissen, S.2
Wollersheim, H.3
Trip, M.D.4
Kastelein, J.J.5
Stalenhoef, A.F.6
-
15
-
-
0032169240
-
Inflammation, pravastatin and risk of coronary events after myocardial infarction in patients with average cholesterol levels
-
Ridker P.M., Rifai N., Pfeffer M.A., Sacks F.M., Moye L.A., Goldman S., Flaker G.C., Braunwald E. Inflammation, pravastatin and risk of coronary events after myocardial infarction in patients with average cholesterol levels. Circulation. 98:1998;839-844.
-
(1998)
Circulation
, vol.98
, pp. 839-844
-
-
Ridker, P.M.1
Rifai, N.2
Pfeffer, M.A.3
Sacks, F.M.4
Moye, L.A.5
Goldman, S.6
Flaker, G.C.7
Braunwald, E.8
-
16
-
-
0035963529
-
Measurement of C-reactive protein for targeting of statin therapy in the primary prevention of acute coronary events
-
Ridker P.M., Rifai N., Clearfield M., Downs J.R., Weis S.E., Miles J.S., Gotto A.M. Jr. Measurement of C-reactive protein for targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med. 344:2001;1959-1965.
-
(2001)
N Engl J Med
, vol.344
, pp. 1959-1965
-
-
Ridker, P.M.1
Rifai, N.2
Clearfield, M.3
Downs, J.R.4
Weis, S.E.5
Miles, J.S.6
Gotto Jr., A.M.7
-
17
-
-
0034074546
-
The role of inflammation in cardiovascular disease
-
(editorial)
-
Kuller L.W., Tracy R.P. The role of inflammation in cardiovascular disease. (editorial) Arterioscler Thromb Vasc Biol. 20:2000;901.
-
(2000)
Arterioscler Thromb Vasc Biol
, vol.20
, pp. 901
-
-
Kuller, L.W.1
Tracy, R.P.2
-
18
-
-
0034304746
-
Lipid-altering efficacy and safety of simvastatin 80 mg/day: Worldwide long-term experience in patients with hypercholesterolemia
-
Davidson M.H., Stein E.A., Hunninghake D.B., Ose L., Dujovne C.A., Insull W. Jr, Bertolami M., Weiss S.R., Kastelein J.J., Scott R.S., et al. Lipid-altering efficacy and safety of simvastatin 80 mg/day: worldwide long-term experience in patients with hypercholesterolemia. Nutr Metab Cardiovasc Dis. 10:2000;253-262.
-
(2000)
Nutr Metab Cardiovasc Dis
, vol.10
, pp. 253-262
-
-
Davidson, M.H.1
Stein, E.A.2
Hunninghake, D.B.3
Ose, L.4
Dujovne, C.A.5
Insull Jr., W.6
Bertolami, M.7
Weiss, S.R.8
Kastelein, J.J.9
Scott, R.S.10
-
19
-
-
84872291610
-
-
July 9, 2003. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. Accessed August 4, 2003
-
Endocrinologic and Metabolic Drugs Advisory Committee (transcript). July 9, 2003. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. Available at: http://www.fda.gov/ohrms/dockets/ac/03/transcripts/3968T1.pdf. Accessed August 4, 2003.
-
Endocrinologic and Metabolic Drugs Advisory Committee (transcript)
-
-
|